The OncoAlert WEEKLY RoundUp 🚨
Covering the TOP of the week Sept 5-11, 2025
REGISTER at
OncoAlert360.com OR
oncoalert.m-pages.com/nhMpwe…
Discussing:
✅ EGFR
#NSCLC : Amivantamab–Lazertinib vs Osimertinib🫁
Amivantamab–lazertinib boosts 3-year OS to 60% vs 51% in untreated EGFR NSCLC, but watch for higher grade ≥3 toxicities ⚠️
✅ SCLC: Tarlatamab PD-L1 Inhibitor
Tarlatamab with PD-L1 therapy shows manageable toxicity and promising median OS of 25.3 months in extensive-stage
#SCLC
✅ COCOON Trial: Skin Toxicity Prevention in EGFR Non Small Cell
#LungCancer 🫁
Simple prophylactic dermatologic care cut grade ≥2 skin toxicity from 75% to 42% and improved QoL in patients on amivantamab-lazertinib ✨
✅A-BRAVE: Adjuvant Avelumab in High-Risk
#TNBC
Avelumab didn’t improve DFS in high-risk early TNBC but hints at better overall survival, regardless of PD-L1 status 💡
✅SONIA ctDNA🧬 Analysis: CDK4/6 Timing in Advanced
#BreastCancer
Pretreatment ctDNA predicts who benefits most from first-line CDK4/6 inhibitors in advanced ER HER2− breast cancer 🧪
✅ Early Detection of Pancreatic Cancer via cfDNA🩸
Machine learning on cfDNA fragmentomics detects early-stage
#PancreaticCancer with >90% accuracy
✅HCC: Epidemiology, Diagnosis & Treatment
Hepatocellular carcinoma is rising due to non-viral causes; early detection and immunotherapy improve outcomes but gaps remain 🏥
#LiverCancer
✅Oligometastatic RCC: Radiotherapy☢️ Alone
Metastasis-directed radiotherapy delayed systemic therapy nearly 3 years in oligometastatic RCC with minimal toxicity.
#KidneyCancer
✅mCRPC: Pembrolizumab Enzalutamide
Adding pembrolizumab to enzalutamide didn’t improve survival but increased grade ≥3 toxicities in chemo-naive mCRPC ❌
#ProstateCancer
✅ PORTEC-3: Adjuvant Chemoradiotherapy in High-Risk
#EndometrialCancer
Chemoradiotherapy boosts 10-year OS to 74% vs 67% with greatest benefit in p53-abnormal tumors 💪
✅🏥 Stage IV Endometrial Cancer: Surgery & Molecular Profiling
Surgery improves survival over chemo alone, and molecular subtype guides prognosis in stage IV endometrial cancer 🔬
✅ ICIs in Advanced
#Sarcoma : IMPRESARC
ICIs show modest efficacy overall, but select subtypes like ASPS, chordoma, SMARCA4-deficient, GIST, and NF1-mutated sarcomas get durable responses ✨
@VivekSubbiah
@Latinamd
@JadChahoud
@Jaskirat__SR
@LuisLara_M
@StephenVLiu
@RManochakian
@MAWi1dgust
@tuttsakhil
@AnaVManana
@APassaroMD
@lungoncdoc
@UOzkerim
@DrRishabhOnco
@M_Torasawa
@chulkimMD
@RenoHemonc
@BZhangMD
@BenWestphalen
@PathologyPat
@yymgcmd
@ErikaHamilton9
@YAbdouMD
@MamMa_mimumemo
@LoiSher
@AnisToumeh
@ChadTangMD
@changjeesuk1
@Sushilberiwal
@_ShankarSiva
@PavlosMsaouel
@Sid423
@drskmishra1984
@urogomez_
@toddscarbrough
@gusviani
@bhavanaparikh1
@MatteoLoverro
@leitaomd